Fig. 3

Correlation analysis of serum SV2A with other biomarkers, and the diagnostic efficiency of serum SV2A combined with these biomarkers in aMCI and AD. Relationship of serum SV2A with (a) serum GFAP, (b) serum p-tau217, and (c) serum NfL. d. Diagnostic efficiency of serum NfL, GFAP, and p-tau217 in Con vs. aMCI. e. Diagnostic efficiency of serum NfL, GFAP, and p-tau217 in Con vs. AD. f. Diagnostic efficiency of serum NfL, GFAP, and p-tau217 in aMCI vs. AD. g. Diagnostic efficiency of serum SV2A + NfL, SV2A + GFAP, SV2A + p-tau217, and SV2A + NfL + GFAP + p-tau217 in Con vs. aMCI. h. Diagnostic efficiency of serum SV2A + NfL, SV2A + GFAP, SV2A + p-tau217, and SV2A + NfL + GFAP + p-tau217 in Con vs. AD. i. Diagnostic efficiency of serum SV2A + NfL, SV2A + GFAP, SV2A + p-tau217, and SV2A + NfL + GFAP + p-tau217 in aMCI vs. AD. Correlation analysis was performed using Spearman’s rank correlation coefficient. Abbreviations: AD, Alzheimer’s disease; aMCI, amnestic mild cognitive impairment; AUC, area under the curve; Con, healthy control; GFAP, glial fibrillary acidic protein; NfL, neurofilament light; p-tau217, phosphorylated tau; SV2A, synaptic vesicle glycoprotein 2 A; vs., versus